Middle East & Africa Multiple Sclerosis Therapeutics Market Size & Outlook
Related Markets
MEA multiple sclerosis therapeutics market highlights
- The MEA multiple sclerosis therapeutics market generated a revenue of USD 931.9 million in 2023.
- The market is expected to grow at a CAGR of 4.5% from 2024 to 2030.
- In terms of segment, immunosuppressants was the largest revenue generating drug class in 2023.
- Immunosuppressants is the most lucrative drug class segment registering the fastest growth during the forecast period.
MEA data book summary
| Market revenue in 2023 | USD 931.9 million |
| Market revenue in 2030 | USD 1,265.0 million |
| Growth rate | 4.5% (CAGR from 2023 to 2030) |
| Largest segment | Immunosuppressants |
| Fastest growing segment | Immunosuppressants |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunosuppressants |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.6% of the global multiple sclerosis therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 9,455.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Multiple Sclerosis Therapeutics Market Scope
Multiple Sclerosis Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck & Co., Inc. | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Horizon Pharma | View profile | 1001-5000 | Northbrook, Illinois, United States, North America | https://www.horizontherapeutics.com |
| Pfizer | View profile | 10001+ | New York, New York, United States, North America | http://www.pfizer.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Middle East & Africa multiple sclerosis therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multiple sclerosis therapeutics market will help companies and investors design strategic landscapes.
Immunosuppressants was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Middle East & Africa multiple sclerosis therapeutics market based on immunosuppressants covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Middle East & Africa multiple sclerosis therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa multiple sclerosis therapeutics market databook
-
Our clientele includes a mix of multiple sclerosis therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa multiple sclerosis therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa multiple sclerosis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
